HeraMED Plans to Release Initial Version of AI-Powered Clinician Assistant in December Quarter; Shares Near Two-Year High

MT Newswires Live

2025/09/22

HeraMED (ASX:HMD) will accelerate the development of its artificial intelligence-powered Clinician Assistant, and the first version is expected to be released in the December quarter, which will include automated notes and workflow support, according to a Monday Australian bourse filing.

The company also developed an ambient scribe tool, which uses AI to automatically generate structured consultation notes during virtual telehealth appointments.

The medical technology company collaborated with the Digital Health Cooperative Research Centre and RMIT University to launch a project to develop AI predictive health models for high-risk pregnancies, including culturally and linguistically diverse populations.

The firm decided to accelerate the development and deployment of its AI-driven technologies and product roadmap initiatives for the HeraCARE platform.

HeraMED's shares rose nearly 3% in recent trading on Monday, hitting their highest since November 2023.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2569277498"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569277498\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569277498?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 11:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569277498","market":"us","top_or_hot":-1,"title":"HeraMED Plans to Release Initial Version of AI-Powered Clinician Assistant in December Quarter; Shares Near Two-Year High","media":"MT Newswires Live","content":"<html><body><p> HeraMED (ASX:HMD) will accelerate the development of its artificial intelligence-powered Clinician Assistant, and the first version is expected to be released in the December quarter, which will include automated notes and workflow support, according to a Monday Australian bourse filing.</p><p>The company also developed an ambient scribe tool, which uses AI to automatically generate structured consultation notes during virtual telehealth appointments.</p><p>The medical technology company collaborated with the Digital Health Cooperative Research Centre and RMIT University to launch a project to develop AI predictive health models for high-risk pregnancies, including culturally and linguistically diverse populations.</p><p>The firm decided to accelerate the development and deployment of its AI-driven technologies and product roadmap initiatives for the HeraCARE platform.</p><p>HeraMED's shares rose nearly 3% in recent trading on Monday, hitting their highest since November 2023.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HeraMED Plans to Release Initial Version of AI-Powered Clinician Assistant in December Quarter; Shares Near Two-Year High</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeraMED Plans to Release Initial Version of AI-Powered Clinician Assistant in December Quarter; Shares Near Two-Year High\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-22 11:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HeraMED (ASX:HMD) will accelerate the development of its artificial intelligence-powered Clinician Assistant, and the first version is expected to be released in the December quarter, which will include automated notes and workflow support, according to a Monday Australian bourse filing.</p><p>The company also developed an ambient scribe tool, which uses AI to automatically generate structured consultation notes during virtual telehealth appointments.</p><p>The medical technology company collaborated with the Digital Health Cooperative Research Centre and RMIT University to launch a project to develop AI predictive health models for high-risk pregnancies, including culturally and linguistically diverse populations.</p><p>The firm decided to accelerate the development and deployment of its AI-driven technologies and product roadmap initiatives for the HeraCARE platform.</p><p>HeraMED's shares rose nearly 3% in recent trading on Monday, hitting their highest since November 2023.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2569277498","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569277498","pubTimestamp":1758511669,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HeraMED  will accelerate the development of its artificial intelligence-powered Clinician Assistant, and the first version is expected to be released in the December quarter, which will include automated notes and workflow support, according to a Monday Australian bourse filing.The company also developed an ambient scribe tool, which uses AI to automatically generate structured consultation notes during virtual telehealth appointments.The medical technology company collaborated with the Digital Health Cooperative Research Centre and RMIT University to launch a project to develop AI predictive health models for high-risk pregnancies, including culturally and linguistically diverse populations.The firm decided to accelerate the development and deployment of its AI-driven technologies and product roadmap initiatives for the HeraCARE platform.HeraMED's shares rose nearly 3% in recent trading on Monday, hitting their highest since November 2023.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","HMD.AU":"HERAMED LTD"},"translate_title":"HeraMED计划在12月季度发布人工智能临床医生助理的初始版本；股价接近两年高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HMD.AU":1},"content_text":"HeraMED (ASX:HMD) will accelerate the development of its artificial intelligence-powered Clinician Assistant, and the first version is expected to be released in the December quarter, which will include automated notes and workflow support, according to a Monday Australian bourse filing.The company also developed an ambient scribe tool, which uses AI to automatically generate structured consultation notes during virtual telehealth appointments.The medical technology company collaborated with the Digital Health Cooperative Research Centre and RMIT University to launch a project to develop AI predictive health models for high-risk pregnancies, including culturally and linguistically diverse populations.The firm decided to accelerate the development and deployment of its AI-driven technologies and product roadmap initiatives for the HeraCARE platform.HeraMED's shares rose nearly 3% in recent trading on Monday, hitting their highest since November 2023.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}